Phase 3 Trial Backs Ivarmacitinib as Effective Oral Option for Moderate to Severe Atopic Dermatitis
China: A recent phase 3 randomized clinical trial has shown that ivarmacitinib significantly improves symptoms in adolescents and adults with moderate to severe atopic dermatitis (AD).
"In the phase 3 randomized clinical trial, once-daily oral ivarmacitinib (4 or 8 mg) led to significant improvements in the signs and symptoms of moderate to severe atopic dermatitis in both adolescents and adults, showing a favorable balance between efficacy and safety compared to placebo," the researchers wrote in JAMA Dermatology.
Ivarmacitinib, a selective oral Janus kinase 1 inhibitor, has previously shown promise in managing moderate to severe atopic dermatitis in adults during phase 2 trials. Building on this evidence, Yan Zhao, Department of Dermatology, Peking University People’s Hospital, Beijing, China, and colleagues aimed to assess its efficacy and safety profile in a broader population, including both adolescents and adults affected by moderate to severe AD.
For this purpose, the researchers conducted a multicenter, double-blind, placebo-controlled phase 3 trial across 53 sites in Canada and China, enrolling patients aged 12 to 75 years with moderate to severe atopic dermatitis. Participants were randomly assigned to receive either 4 mg or 8 mg of oral ivarmacitinib or a placebo once daily for 16 weeks.
The main outcomes assessed were the proportion of patients achieving clear or almost clear skin (IGA score of 0 or 1 with at least a 2-grade improvement) and a 75% improvement in Eczema Area and Severity Index (EASI-75) by week 16.
The study led to the following findings:
- A total of 336 patients were randomized, with an average age of 31.1 years; 63.4% were male and 85.1% were Asian. Of these, 113 received 4 mg ivarmacitinib, 112 received 8 mg ivarmacitinib, and 111 received a placebo.
- At week 16, 36.3% of patients on 4 mg and 42.0% on 8 mg ivarmacitinib achieved clear or almost clear skin with at least a 2-grade improvement in IGA score, compared to just 9.0% in the placebo group.
- EASI-75 responses were also better with treatment: 54.0% in the 4 mg group and 66.1% in the 8 mg group, compared to 21.6% in the placebo group.
- Treatment-emergent adverse events were reported in 69.0% of the 4 mg group, 66.1% of the 8 mg group, and 64.9% of the placebo group.
- Serious adverse events were low across all groups, occurring in 2.7% of the 4 mg group, 1.8% of the 8 mg group, and 2.7% of the placebo group.
"These findings highlight ivarmacitinib as a promising and effective oral treatment with a favorable risk-benefit profile for moderate to severe atopic dermatitis, especially in patients who do not respond well to topical therapies," the authors concluded.
Reference:
Zhao Y, Gooderham M, Yang B, et al. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. Published online April 30, 2025. doi:10.1001/jamadermatol.2025.0982
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.